Which anthelmintic is contraindicated in patients with liver disease?

The correct choice is Albendazole, which is contraindicated in patients with liver disease due to its metabolism and potential for causing hepatotoxicity. Albendazole is extensively metabolized in the liver, and its metabolites can accumulate in individuals with compromised liver function. This can lead to increased levels of the drug in the system, heightening the risk of liver damage and adverse effects.

When considering the other options, while Mebendazole, Praziquantel, and Ivermectin do have side effects and may require caution in certain populations, they do not carry the same level of contraindication specifically related to liver disease as Albendazole does. Praziquantel is usually well-tolerated and does not have significant hepatotoxic potential, and Ivermectin's use is generally safe in patients with liver conditions, although it should still be approached with caution. Mebendazole has minimal liver involvement in its metabolism and is not contraindicated for patients with liver disease. Therefore, Albendazole's unique metabolic pathway and the associated risks make it the correct answer in this context.